Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal has been in preparation. The South Korean firm just agreed to buy Biogen out of their ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best ...

Biogen's stock underperformed in 2024 due to poor sales of Leqembi and declining multiple sclerosis revenues, despite efforts to diversify its pipeline. Leqembi's market struggles continue, with ...

Across the recent three months, 18 analysts have shared their insights on Biogen BIIB, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will ...

Shares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline late Friday. Little has gone right for Sage in recent years ...